Engineering UDP ‐sugar synthesis pathways for exopolysaccharide biosynthesis in Streptococcus thermophilus AR333
Journal of the Science of Food and Agriculture · 2025
DOI: 10.1002/jsfa.14206 ↗At a glance
Journal article in Journal of the Science of Food and Agriculture, 2025. Written by Yizhou Fan and 6 co-authors. Institution: Shanghai Engineering Research Center of Food Microbiology, School of Health Science and Engineering, University of Shanghai for Science and Technolog…. Major MEDLINE topics: Streptococcus thermophilus, Polysaccharides, Bacterial, Uridine Diphosphate Sugars. Cited 6 times so far (Crossref); 29 references. Funded by: Academician/expert workstation in Yunnan, China, Natural Science Foundation of Shanghai, Shanghai Engineering Research Center of Food Microbiology.
Abstract (original language)
BACKGROUND Exopolysaccharide (EPS) produced by Streptococcus thermophilus can significantly improve the viscosity, texture and taste of dairy products, which have broad application potential in the food industry. However, EPS production is typically low (< 100 mg L −1 ) in S. thermophilus , making it difficult to meet industrialization requirements. The utilization of metabolic engineering for genetic modification of S. thermophilus is an efficient approach to enhance EPS biosynthesis. RESULTS To our knowledge, there is lack of systematic investigation on engineering UDP‐sugar synthetic pathways for EPS production in S. thermophilus . In the present study, the biosynthetic genes of EPS precursors UDP‐glucose and UDP‐galactose were regulated for improving EPS production in S. thermophilus AR333. Compared with the control, engineered strains by single overexpression of eight EPS precursor genes increased EPS production by 7–31%, respectively. Among of them, overexpressing glk encoding glucokinase and galE1 encoding UDP‐galactose‐4‐epimase led to 275.37 and 288.65 mg L −1 of EPS production, respectively. Moreover, co‐overexpression of lacZ encoding β‐galactosidase and galE1 achieved a remarkable 49% increase in the EPS production (329.51 mg L −1 ). Transcriptional analysis further suggested that enhanced EPS synthesis in engineered strain can attributed to the upregulation of precursor genes and clusters of EPS genes. CONCLUSION Our results showed that engineered UDP‐sugar synthesis is an efficient strategy to boost EPS production in S. thermophilus . © 2025 Society of Chemical Industry.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Shanghai Engineering Research Center of Food Microbiology, School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.
ORCID profiles: Xin Song, Guangqiang Wang, Yongjun Xia, Lianzhong Ai, Zhiqiang Xiong
Funding
- Academician/expert workstation in Yunnan, China
- Natural Science Foundation of Shanghai
- Shanghai Engineering Research Center of Food Microbiology
- National Natural Science Foundation of China
- Shanghai Education committee scientific research innovation projects
- National Science Fund for Distinguished Young Scholars
- Shanghai Research Center for Food Microbiology Engineering and Technology
Cite
APA
Fan, Y., Shi, J., Song, X., Wang, G., Xia, Y., Ai, L., & Xiong, Z. (2025). Engineering UDP ‐sugar synthesis pathways for exopolysaccharide biosynthesis in Streptococcus thermophilus AR333. Journal of the Science of Food and Agriculture. https://doi.org/10.1002/jsfa.14206
Vancouver
Fan Y, Shi J, Song X, Wang G, Xia Y, Ai L, et al. Engineering UDP ‐sugar synthesis pathways for exopolysaccharide biosynthesis in Streptococcus thermophilus AR333. Journal of the Science of Food and Agriculture. 2025. doi:10.1002/jsfa.14206
BibTeX
@article{Fan2025,
author = {Fan, Yizhou and Shi, Junkang and Song, Xin and Wang, Guangqiang and Xia, Yongjun and Ai, Lianzhong and Xiong, Zhiqiang},
title = {Engineering UDP ‐sugar synthesis pathways for exopolysaccharide biosynthesis in Streptococcus thermophilus AR333},
journal = {Journal of the Science of Food and Agriculture},
year = {2025},
doi = {10.1002/jsfa.14206}
}
EUVIMED